The FDA on June 22,2020 granted accelerated approval to XPOVIO® for adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Otherwise Specified, including DLBCL arising from Follicular Lymphoma, after at least 2 lines of systemic therapy. XPOVIO® is a product of Karyopharm Therapeutics.
Other Pages – Bottom Ad
Advertisement
Subscribe
